Da fikk insulin-release. Kan vi få enda et før jul om komplikasjoner? Jan har vel også til vane å komme med en “julehilsen”.
Follicum annnouces positive human ex vivo data from preclinical diabetes studies of new class of FOL peptides
Follicum
17.12.2019, 08:39·Cision
Follicum AB (“Follicum” or “the Company”) today announces that data from studies on human Langerhans islets have shown positive effects on insulin release in line with the previously reported results on beta cells isolated from animals. The studies were performed through two different collaborations, one with Lund University and one with InSphero, Switzerland and showed similar results.
The Company’s development of a peptide-based treatment of diabetes and its complications is proceeding according to plan. Follicum has studied the ability of peptides to induce insulin secretion in Langerhans islets derived from human donors. The studies show that in these ex vivo studies the peptides has the ability to release insulin in line with a GLP-1 analogue. Thus the effect of the peptides on beta cell lines previously reported can be reproduced in human material.
These studies are two of several studies that is presently ongoing to further substantiate the therapeutic value of FOL-peptides in various diabetic complications.
CEO Jan Alenfall comments
- We are very pleased to be able to report these findings from two different labs. It is important to report effects in human material at an early stage. The results of these studies show that Follicum’s peptides are as potent as a GLP-1 analogue in human material.
About Diabetes
Diabetes is rapidly increasing globally. The disease is characterized by poor blood sugar control due to defective insulin signalling, which causes serious sequelae such as cardiovascular disease, renal failure, obesity, blindness and diabetic foot ulcers. Diabetes as well as its accompanying illnesses represent a major burden, partly for the individual patient, but also for the entire health care system. There is thus an already large and growing global need for new therapies that address effective control of glucose levels in combination with preventive effects on the various diabetic complications.
For further information, please contact:
Jan Alenfall - CEO, Follicum AB
Ikke værst å itillegg få valuta-gevinst i samme slengen 
Deltok i emisjonen ifjord også. Ble en fin reise 
